Soluble CD40 ligand levels in patients with hypertensionSONMEZ, Alper; DOGRU, T; YILMAZ, M. I et al.Clinical and experimental hypertension (1993). 2005, Vol 27, Num 8, pp 629-634, issn 1064-1963, 6 p.Article

Is soluble CD40 ligand a mediator of angiogenesis in patients with coronary artery disease?HOONG SERN LIM; TAYEBJEE, Muzahir H; TAN, Kiat T et al.Thrombosis research. 2008, Vol 122, Num 3, pp 307-313, issn 0049-3848, 7 p.Article

Elevated circulating soluble form of CD40 ligand in patients with cardiac syndrome XDOMINGUEZ-RODRIGUEZ, Alberto; ABREU-GONZALEZ, Pedro; AVANZAS, Pablo et al.Atherosclerosis. 2010, Vol 213, Num 2, pp 637-641, issn 0021-9150, 5 p.Article

Soluble CD40 ligand:interleukin-10 ratio predicts in-hospital adverse events in patients with ST-segment elevation myocardial infarctionDOMINGUEZ-RODRIGUEZ, Alberto; ABREU-GONZALEZ, Pedro; GARCIA-GONZALEZ, Martin J et al.Thrombosis research. 2007, Vol 121, Num 3, pp 293-299, issn 0049-3848, 7 p.Article

Significant correlation between the CD63 assay and the histamine release assay in chronic urticariaSZEGEDI, A; IRINYI, B; GAL, M et al.British journal of dermatology (1951). 2006, Vol 155, Num 1, pp 67-75, issn 0007-0963, 9 p.Article

Analysis of serum soluble CD40 ligand in patients with influenza virus-associated encephalopathyICHIYAMA, Takashi; MORISHIMA, Tsuneo; SUENAGA, Naoko et al.Journal of the neurological sciences. 2005, Vol 239, Num 1, pp 53-57, issn 0022-510X, 5 p.Article

Diurnal variation of soluble CD40 ligand in patients with acute coronary syndrome. Soluble CD40 ligand and diurnal variationDOMINGUEZ-RODRIGUEZ, Alberto; ABREU-GONZALEZ, Pedro; GARCIA-GONZALEZ, Martin J et al.Thrombosis research. 2009, Vol 123, Num 4, pp 617-621, issn 0049-3848, 5 p.Article

Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus : effect of improved metabolic controlCIPOLLONE, F; CHIARELLI, F; TUMINI, S et al.Diabetologia (Berlin). 2005, Vol 48, Num 6, pp 1216-1224, issn 0012-186X, 9 p.Article

Artifactual elevation of plasma sCD40L by residual platelets in patients with coronary artery diseaseLEE, Regent; ANTONOPOULOS, Alexios S; ALEXOPOULOU, Zoi et al.International journal of cardiology. 2013, Vol 168, Num 2, pp 1648-1650, issn 0167-5273, 3 p.Article

Elevations in soluble CD40 ligand in patients with high platelet aggregability undergoing percutaneous coronary interventionOBRADOVIC, Slobodan D; ANTOVIC, Jovan P; ANTONIJEVIC, Nebojsa M et al.Blood coagulation & fibrinolysis. 2009, Vol 20, Num 4, pp 283-289, issn 0957-5235, 7 p.Article

Preoperative sCD40L Levels Predict Risk of Atrial Fibrillation After Off-Pump Coronary Artery Bypass Graft SurgeryANTONIADES, Charalambos; VAN-ASSCHE, Tim; TAGGART, David et al.Circulation (New York, N.Y.). 2009, Vol 120, Num 11, issn 0009-7322, S170-S176, SUP1Conference Paper

Transcoronary concentration gradient of sCD40L and hsCRP in patients with coronary heart diseaseYING WANG; LI LI; TAN, Hong-Wei et al.Clinical cardiology (Mahwah, NJ). 2007, Vol 30, Num 2, pp 86-91, issn 0160-9289, 6 p.Article

Association between enhanced soluble CD40 ligand and prothrombotic state in inflammatory bowel diseaseKOUTROUBAKIS, Ioannis E; THEODOROPOULOU, Angeliki; XIDAKIS, Costas et al.European journal of gastroenterology & hepatology. 2004, Vol 16, Num 11, pp 1147-1152, issn 0954-691X, 6 p.Article

Enhanced P-selectin expression and increased soluble CD4o Ligand in patients with Type 1 diabetes mellitus and microangiopathy: evidence for platelet hyperactivity and chronic inflammationYNGEN, M; ÖSTENSON, C.-G; HU, H et al.Diabetologia (Berlin). 2004, Vol 47, Num 3, pp 537-540, issn 0012-186X, 4 p.Article

Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseasesGOULES, Andreas; TZIOUFAS, Athanasios G; MANOUSAKIS, Menelaos N et al.Journal of autoimmunity (Print). 2006, Vol 26, Num 3, pp 165-171, issn 0896-8411, 7 p.Article

Thromboxane A₂ promotes soluble CD40 ligand release from human plateletsENOMOTO, Yukiko; ADACHI, Seiji; KOZAWA, Osamu et al.Atherosclerosis. 2010, Vol 209, Num 2, pp 415-421, issn 0021-9150, 7 p.Article

Soluble CD40 ligand and interleukin-6 in the coronary circulation after acute myocardial infarctionOHASHI, Yoshitaka; KAWASHIMA, Seinosuke; MORI, Takao et al.International journal of cardiology. 2006, Vol 112, Num 1, pp 52-58, issn 0167-5273, 7 p.Article

Increased levels of resistin in rotating shift workers: A potential mediator of cardiovascular risk associated with circadian misalignmentBURGUENO, Adriana; GEMMA, Carolina; FERNANDEZ GIANOTTI, Tomas et al.Atherosclerosis. 2010, Vol 210, Num 2, pp 625-629, issn 0021-9150, 5 p.Article

The relationship between soluble CD40 ligand levels and framingham coronary heart disease risk score in healthy volunteersVERMA, Subodh; WANG, Chao-Hung; LI, Shu-Hong et al.Atherosclerosis. 2005, Vol 182, Num 2, pp 361-365, issn 0021-9150, 5 p.Article

Soluble CD40 Ligand (sCD40L) Provides a New Delivery System for Targeted Treatment: sCD40L-Caspase 3 Chimeric Protein for Treating B-Cell MalignanciesKEDAR, Rotem; SABAG, Ofra; LICTHENSTEIN, Michal et al.Cancer. 2012, Vol 118, Num 24, pp 6089-6104, issn 0008-543X, 16 p.Article

Serum brain-derived neurotrophic factor and platelet activation evaluated by soluble P-selectin and soluble CD-40-ligand in patients with acute myocardial infarctionLORGIS, Luc; AMOUREUX, Sebastien; COTTIN, Yves et al.Fundamental & clinical pharmacology. 2010, Vol 24, Num 4, pp 525-530, issn 0767-3981, 6 p.Article

Effect of continuous positive airway pressure on soluble CD40 ligand in patients with obstructive sleep apnea syndromeKOBAYASHI, Kazuyuki; NISHIMURA, Yoshihiro; SHIMADA, Temiko et al.Chest. 2006, Vol 129, Num 3, pp 632-637, issn 0012-3692, 6 p.Article

High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation : Relationship to stroke risk factors, stroke risk stratification schema, and prognosisLIP, Gregory Y. H; PATEL, Jeetesh V; HUGHES, Elizabeth et al.Stroke (1970). 2007, Vol 38, Num 4, pp 1229-1237, issn 0039-2499, 9 p.Article

Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention—Effects on soluble CD40 ligand concentrationsDOMINGUEZ-RODRIGUEZ, Alberto; ABREU-GONZALEZ, Pedro; AVANZAS, Pablo et al.Atherosclerosis. 2009, Vol 206, Num 2, pp 523-527, issn 0021-9150, 5 p.Article

A comparison of anticoagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagulationRAY, Michael J; JUNEJA, Manjeet; BETT, Nicholas et al.EuroIntervention. 2009, Vol 5, Num 3, pp 330-335, issn 1774-024X, 6 p.Article